Ligand Pharmaceuticals
LGND
221 hedge funds and large institutions have $2.51B invested in Ligand Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 70 increasing their positions, 82 reducing their positions, and 14 closing their positions.
284% more call options, than puts
Call options by funds: $24.9M | Put options by funds: $6.48M
129% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 14
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
10% more capital invested
Capital invested by funds: $2.28B → $2.51B (+$229M)
7% more funds holding
Funds holding: 207 → 221 (+14)
1.44% less ownership
Funds ownership: 157.68% → 156.24% (-1.4%)
15% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 82
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.01M |
| 2 |
Millennium Management
New York
|
+$6.29M |
| 3 |
Impax Asset Management Group
London,
United Kingdom
|
+$5.26M |
| 4 |
Goldman Sachs
New York
|
+$4.08M |
| 5 |
SCM
Snyder Capital Management
San Francisco,
California
|
+$4.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$9.23M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$7.09M |
| 3 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
-$6.97M |
| 4 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
-$6.72M |
| 5 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$5.21M |
LGND Hedge Fund Activity: Q4 2021 in Review
221 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q4 2021, worth a combined $2.51B — up 10% from $2.28B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new LGND positions and 14 closed out — a net gain of 18 holders — while 70 added to existing stakes and 82 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $8.01M. The largest seller was Invesco, cutting an estimated $9.23M.
- 221 institutional investors held Ligand Pharmaceuticals (LGND) as of Q4 2021, up from 207 in Q3 2021.
- Funds reported $2.51B of Ligand Pharmaceuticals stock for Q4 2021, up 10% quarter-over-quarter.
- 32 funds opened new Ligand Pharmaceuticals positions in Q4 2021 and 14 closed out, a net change of +18 holders.
- The largest Ligand Pharmaceuticals buyer in Q4 2021 was Point72 Asset Management, an estimated $8.01M added.
- The largest Ligand Pharmaceuticals seller in Q4 2021 was Invesco, an estimated $9.23M sold.
Based on aggregated 13F filings for Q4 2021.